PCSK9 and acute myocardial infarction: In human studies in adults, serum PCSK9 levels are positively associated with acute myocardial infarction [27] and high-sensitivity C-reactive protein levels [28], whereas PCSK9 inhibitors such as evolocumab or alirocumab reduce the risk of recurrent ischemic cardiovascular events [29, 30].